Themis Medicare Limited (THEMISMED.BO)
INR 127.5
(-1.54%)
INR 127.5
(-1.54%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 392.58 Million INR | -31.07% |
| 2022 | 569.56 Million INR | -33.89% |
| 2021 | 861.55 Million INR | 110.39% |
| 2020 | 409.49 Million INR | 49.15% |
| 2019 | 274.55 Million INR | 582.03% |
| 2018 | -56.95 Million INR | -132.07% |
| 2017 | 177.6 Million INR | -30.8% |
| 2016 | 256.63 Million INR | -2.31% |
| 2015 | 262.71 Million INR | 53.26% |
| 2014 | 171.41 Million INR | -3.63% |
| 2013 | 177.87 Million INR | 125.45% |
| 2012 | 78.89 Million INR | 138.46% |
| 2011 | -205.13 Million INR | -195.19% |
| 2010 | 215.48 Million INR | -25.87% |
| 2009 | 290.69 Million INR | 383.78% |
| 2008 | 60.08 Million INR | -79.57% |
| 2007 | 294.07 Million INR | 28.05% |
| 2006 | 229.66 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 146.77 Million INR | -45.17% |
| 2024 Q1 | 267.69 Million INR | 328.98% |
| 2023 Q2 | 93.35 Million INR | -50.12% |
| 2023 Q3 | 49.66 Million INR | -46.79% |
| 2023 Q4 | 62.4 Million INR | 25.64% |
| 2023 FY | 392.58 Million INR | -31.07% |
| 2023 Q1 | 187.16 Million INR | 143.57% |
| 2022 Q4 | 76.84 Million INR | -38.98% |
| 2022 Q1 | 178.99 Million INR | 48.9% |
| 2022 FY | 569.56 Million INR | -33.89% |
| 2022 Q2 | 187.78 Million INR | 4.91% |
| 2022 Q3 | 125.93 Million INR | -32.94% |
| 2021 Q4 | 120.2 Million INR | -19.47% |
| 2021 Q1 | 381.22 Million INR | 286.28% |
| 2021 FY | 861.55 Million INR | 110.39% |
| 2021 Q2 | 210.85 Million INR | -44.69% |
| 2021 Q3 | 149.27 Million INR | -29.21% |
| 2020 Q4 | 98.69 Million INR | -40.93% |
| 2020 Q3 | 167.08 Million INR | 36.27% |
| 2020 FY | 409.49 Million INR | 49.15% |
| 2020 Q1 | 127.28 Million INR | 5.69% |
| 2020 Q2 | 122.61 Million INR | -3.67% |
| 2019 Q2 | 44.93 Million INR | -44.98% |
| 2019 Q4 | 120.43 Million INR | -9.54% |
| 2019 Q1 | 81.67 Million INR | 181.14% |
| 2019 FY | 274.55 Million INR | 582.03% |
| 2019 Q3 | 133.13 Million INR | 196.27% |
| 2018 Q3 | 23.76 Million INR | 10.56% |
| 2018 Q2 | 21.49 Million INR | -36.08% |
| 2018 Q1 | 33.62 Million INR | -59.46% |
| 2018 FY | -56.95 Million INR | -132.07% |
| 2018 Q4 | -100.66 Million INR | -523.62% |
| 2017 Q4 | 82.94 Million INR | 67.25% |
| 2017 FY | 177.6 Million INR | -30.8% |
| 2017 Q2 | 100.94 Million INR | 0.0% |
| 2017 Q3 | 49.59 Million INR | -50.87% |
| 2016 Q3 | 107.14 Million INR | 380.17% |
| 2016 FY | 256.63 Million INR | -2.31% |
| 2016 Q2 | 22.31 Million INR | -77.41% |
| 2016 Q1 | 98.79 Million INR | 57.17% |
| 2016 Q4 | 64.57 Million INR | -39.74% |
| 2015 Q1 | 86.51 Million INR | 234.16% |
| 2015 Q3 | 73.23 Million INR | -23.1% |
| 2015 Q4 | 62.85 Million INR | -14.17% |
| 2015 FY | 262.71 Million INR | 53.26% |
| 2015 Q2 | 95.22 Million INR | 10.07% |
| 2014 Q3 | 58.97 Million INR | 89.44% |
| 2014 FY | 171.41 Million INR | -3.63% |
| 2014 Q2 | 31.13 Million INR | 0.0% |
| 2014 Q4 | 25.89 Million INR | -56.1% |
| 2013 FY | 177.87 Million INR | 125.45% |
| 2012 Q1 | 44.57 Million INR | 0.0% |
| 2012 FY | 78.89 Million INR | 138.46% |
| 2012 Q3 | -13.35 Million INR | -130.96% |
| 2012 Q2 | 43.13 Million INR | -3.23% |
| 2012 Q4 | 4.1 Million INR | 130.73% |
| 2011 FY | -205.13 Million INR | -195.19% |
| 2010 FY | 215.48 Million INR | -25.87% |
| 2009 FY | 290.69 Million INR | 383.78% |
| 2008 FY | 60.08 Million INR | -79.57% |
| 2007 FY | 294.07 Million INR | 28.05% |
| 2006 FY | 229.66 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alkem Laboratories Limited | 19.46 Billion INR | 97.983% |
| Amrutanjan Health Care Limited | 457.54 Million INR | 14.196% |
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 93.182% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | 77.142% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 99.07% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -4229.055% |
| Eris Lifesciences Limited | 5.18 Billion INR | 92.424% |
| FDC Limited | 2.98 Billion INR | 86.853% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 95.628% |
| Ipca Laboratories Limited | 7.98 Billion INR | 95.081% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | 22.738% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 358.355% |
| Laurus Labs Limited | 3.94 Billion INR | 90.058% |
| Lupin Limited | 28.04 Billion INR | 98.6% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -291.415% |
| Megasoft Limited | -121.1 Million INR | 424.175% |
| NATCO Pharma Limited | 25.96 Billion INR | 98.488% |
| Piramal Pharma Limited | 4.55 Billion INR | 91.385% |
| Sigachi Industries Limited | 1.47 Billion INR | 73.364% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 110.189% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 99.624% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 91.48% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -57.507% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 98.45% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | 31.09% |
| Windlas Biotech Limited | 1.29 Billion INR | 69.775% |
| ZIM Laboratories Limited | 253.82 Million INR | -54.667% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 99.089% |
| Ajanta Pharma Limited | 19.67 Billion INR | 98.005% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 91.119% |
| Achyut Healthcare Limited | 4.43 Million INR | -8746.079% |
| Lasa Supergenerics Limited | -458 Million INR | 185.717% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 109.54% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 87.45% |
| Alpa Laboratories Limited | 184.49 Million INR | -112.789% |
| Gufic Biosciences Limited | 1.32 Billion INR | 70.48% |
| Ind-Swift Limited | 1.22 Billion INR | 67.977% |
| Indoco Remedies Limited | 1.29 Billion INR | 69.627% |
| Hester Biosciences Limited | 364.81 Million INR | -7.615% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | 68.108% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| RPG Life Sciences Limited | 2.29 Billion INR | 82.874% |
| Mankind Pharma Limited | 21.51 Billion INR | 98.176% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 93.962% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Bal Pharma Limited | 233.9 Million INR | -67.838% |
| Strides Pharma Science Limited | 5.22 Billion INR | 92.487% |
| Venus Remedies Limited | 534.65 Million INR | 26.571% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 92.434% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 99.42% |
| Divi's Laboratories Limited | 33.08 Billion INR | 98.813% |
| Nectar Lifesciences Limited | 923.8 Million INR | 57.503% |
| Shilpa Medicare Limited | 1.36 Billion INR | 71.266% |
| Aarti Drugs Limited | 7.14 Billion INR | 94.508% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | 75.414% |
| Suven Life Sciences Limited | -1.22 Billion INR | 132.027% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 97.251% |
| Hikal Limited | 32.11 Million INR | -1122.638% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 85.909% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | 37.336% |
| Granules India Limited | 6.81 Billion INR | 94.241% |
| Wockhardt Limited | -670 Million INR | 158.595% |
| Brooks Laboratories Limited | 14.44 Million INR | -2618.76% |
| Neuland Laboratories Limited | 5.31 Billion INR | 92.618% |
| Morepen Laboratories Limited | 4.17 Billion INR | 90.594% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -88.699% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -1329.78% |